Beam shares results from seven patients who received gene-edited sickle cell therapy

Lei Lei Wu

News Reporter

SAN DIEGO — Beam Therapeutics now has trial data from seven patients who have received its gene-edited sickle cell therapy, showing promising early signs that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Beam shares results from seven patients who received gene-edited sickle cell therapy

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Maze files for first biotech IPO of 2025, following $115M funding boost

Beam shares re­sults from sev­en pa­tients who re­ceived gene-edit­ed sick­le cell ther­a­py

Lei Lei Wu

News Reporter

Sign up to read this article for free.

more like this

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Beam shares results from seven patients who received gene-edited sickle cell therapy

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Maze files for first biotech IPO of 2025, following $115M funding boost